NovoCure (NVCR) closed the last trading session at $20.80, gaining 19.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $26.29 indicates a 26.4% upside potential. However, an impressive consensus price target is not the only factor that indicates a potential upside in NVCR. This view is strengthened by the agreement among analysts that the company will report better earnings than ...

follows below Published on TradingView.com, Jul 26, 2024 08:08 UTC-4 NovoCure Limited, 1D, Cboe One 18.65 -0.14 (-0.75%) Vol. 2.048.M. 40.00 36.00 32.00 28.00 24.00 12.00 图 2024 "I"/ TradingView This is a wearable, portable, and FDA-approved glioblastoma (GBM) treatment for adult patients. The company is currently in late stage pivotal trial development utilizing Optune GIO concurrent with chemo radiation (TRIDENT, top-line results in 2026) and also with pembrolizumab to TTFields and temozolomide (KEYNOTE D ...

Over the last four quarters, the company has surpassed consensus EPS estimates four times. NovoCure, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $150.36 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 10.18%. This compares to year-ago revenues of $126.05 million. The company has topped consensus revenue estimates three times over the last four quarters. NovoCure shares have added about 25.9% since the beginning of the year ver ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCure Limited (Exact Name of Registrant as Specified in Its Char ...

"The second quarter was a period of consistent execution at Novocure," said Asaf Danziger, Novocure's Chief Executive Officer. "We began the year with three key objectives – grow our commercial business in glioblastoma, launch our next indication in non-small cell lung cancer, and deliver on the promise of our clinical and product development pipeline. I am pleased to share we have made significant progress on all fronts this quarter.""The second quarter was a period of consistent execution at Novocure," sa ...

NovoCure (NVCR) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.28%. A quarter ago, it was expected that this oncology drug developer would post a loss of $0.53 per share when it actually produced a loss of $0.45, delivering a surprise of 15.09%.Over the last four quarters, the company has ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q (Exact Name of Registrant as Specified in Its Charter) For the quarterly period ended March 31, 2024 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification No.) or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Jersey 98-1057807 For the transition period from to Commission File Number 001- ...

Exhibit 99.1 Novocure Reports First Quarter 2024 Financial Results Quarterly net revenues of $139 million, up 13% year-over-year, with 3,845 active patients on therapy as of March 31, 2024 Phase 3 METIS trial in brain metastases from non-small cell lung cancer met primary endpoint and will be presented as late-breaking abstract at ASCO 2024 LUNAR PMA application for TTFields in NSCLC Day 100 FDA meeting complete Root, Switzerland – Novocure (NASDAQ: NVCR) today reported financial results for the quarter end ...

q4 2023 selected financial highlights patientforward® @ 2024 Novocure GmbH 9 novocure® Optune Lua® and Optune Gio® indications for use and important safety information novocure® | --- | --- | --- | --- | |----------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | Novocure | | | | | Q4 2023 Earnings Thursday, February 22, 2024 | | | | forward-looking statements ln addition to historical facts or statements of current condition, this presentation may contain forwar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________ FORM 10-K ______________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Nu ...